What is Achilles Therapeutics plc (ACHL) stock price today?

Achilles Therapeutics plc (ACHL) is currently trading at $1.48, up 0.68% today.

What is ACHL P/E ratio?

Achilles Therapeutics plc's P/E ratio is -0.85. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ACHL return on equity (ROE)?

Achilles Therapeutics plc's return on equity (ROE) is -41.05%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Achilles Therapeutics plc's market cap?

Achilles Therapeutics plc has a market capitalization of $60.83M.

NASDAQ · Biotechnology

Achilles Therapeutics plc (ACHL) Stock

$1.48 +0.68% NASDAQ: ACHL Healthcare

Valuation

Metric	Value
Price	$1.48
Market Cap	$60.83M
P/E Ratio	-0.85
P/B Ratio	0.42
P/S Ratio	0.00
EPS (TTM)	$-1.74
52-Week High	$1.51
52-Week Low	$0.63
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-41.05%
ROA	-43.15%
ROCE	-52.09%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.03
Current Ratio	8.57

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-14.0M	$-34.0M	$-64.0M	$-78.0M	$-75.0M
Net Profit	$-14.0M	$-33.0M	$-61.0M	$-71.0M	$-70.0M
EPS	$-20.48	$-0.82	$-2.13	$-1.82	$-1.74
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$105.0M	$219.0M	$317.0M	$220.0M	$161.0M
Total Liabilities	$4.0M	$30.0M	$28.0M	$23.0M	$19.0M
Cash	$98.0M	$178.0M	$266.0M	$173.0M	$132.0M
Borrowings	$0	$16.0M	$12.0M	$9.0M	$5.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-14.0M	$-25.0M	$-59.0M	$-60.0M	$-48.0M
Investing Cash Flow	$-2.0M	$-24.0M	$-23.0M	$-23.0M	$-2.0M
Financing Cash Flow	$0	$0	$161.0M	$0	$0
Net Cash Flow	$87.0M	$80.0M	$89.0M	$-93.0M	$-42.0M
Free Cash Flow	$-15.0M	$-37.0M	$-67.0M	$-67.0M	$-50.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.07
EV / EBITDA	0.94
FCF Yield	-81.46%
Quick Ratio	8.57
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALVRAlloVir, Inc.	$9.81	+4.14%	-1.89	$49.48M	0.00%
HTBXHeat Biologics, Inc.	$2.38	+0.42%	-1.87	$61.07M	0.00%
KRONKronos Bio, Inc.	$0.88	+1.49%	-0.62	$53.65M	0.00%
QNCXQuince Therapeutics, Inc.	$31.73	+8.07%	-0.46	$8.83M	0.00%
RNTXRein Therapeutics, Inc.	$0.59	-22.34%	-0.44	$16.38M	0.00%

About Achilles Therapeutics plc

Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.

Achilles Therapeutics plc is headquartered in GB.

Achilles Therapeutics plc (ACHL) stock trades at $1.48 with a market capitalization of $60.83M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.85, reflecting a net loss over the last twelve months, price-to-book of 0.42, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.63 and $1.51, and currently trades 2.0% below its 52-week high.

On profitability, Achilles Therapeutics plc generates a return on equity (ROE) of -41.05% (negative, reflecting a net loss), return on capital employed of -52.09%.

Official website: www.achillestx.com